Top Page
Shanghai Fosun Pharmaceutical (Group) Co
(2196)
Shanghai Fosun Pharmaceutical (Group) Co (2196) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Fosun Pharmaceutical (Group) Co Business Overview & Revenue Model
Shanghai Fosun Pharmaceutical (Group) Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.12B | 41.07B | 41.40B | 43.95B | 39.01B | 30.31B |
| Gross Profit | 19.09B | 19.70B | 19.68B | 20.78B | 18.78B | 16.88B |
| EBITDA | 6.33B | 8.60B | 7.55B | 7.87B | 8.70B | 7.23B |
| Net Income | 3.25B | 2.77B | 2.39B | 3.73B | 4.73B | 3.66B |
Balance Sheet | ||||||
| Total Assets | 118.83B | 117.46B | 113.47B | 107.16B | 93.29B | 83.69B |
| Cash, Cash Equivalents and Short-Term Investments | 15.64B | 16.12B | 15.58B | 17.17B | 14.55B | 11.93B |
| Total Debt | 32.21B | 31.70B | 30.28B | 30.25B | 24.25B | 24.01B |
| Total Liabilities | 58.51B | 57.53B | 56.85B | 53.05B | 44.92B | 37.70B |
| Stockholders Equity | 47.40B | 47.26B | 45.68B | 44.58B | 39.19B | 37.00B |
Cash Flow | ||||||
| Free Cash Flow | -766.40M | 66.79M | ― | ― | ― | ― |
| Operating Cash Flow | 4.70B | 4.48B | 3.41B | 4.22B | 3.95B | 2.58B |
| Investing Cash Flow | -1.64B | -3.61B | -3.82B | ― | ― | ― |
| Financing Cash Flow | -3.55B | -1.00B | ― | 4.43B | ― | 1.47B |
Shanghai Fosun Pharmaceutical (Group) Co Technical Analysis
Shanghai Fosun Pharmaceutical (Group) Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$43.86B | 9.48 | 7.86% | 7.15% | 1.13% | -13.53% | |
73 Outperform | HK$28.04B | 13.30 | 12.65% | 3.13% | 10.56% | -13.58% | |
71 Outperform | HK$33.02B | 11.57 | 14.91% | 4.09% | -0.45% | 9.00% | |
68 Neutral | HK$28.96B | 9.52 | 5.90% | 2.95% | ― | ― | |
64 Neutral | HK$23.60B | 6.58 | 21.02% | 5.11% | 0.39% | 4.94% | |
53 Neutral | HK$76.85B | 15.87 | 6.75% | 1.69% | -1.12% | 76.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Shanghai Fosun Pharmaceutical (Group) Co Corporate Events
Shanghai Fosun Pharmaceutical’s subsidiary Chengdu Xingrui Jingxuan Therapeutics has initiated a Phase I clinical trial in mainland China for SRT-007, a theranostic radiopharmaceutical targeting PSMA-positive metastatic castration‑resistant prostate cancer, marking an advancement in the group’s oncology innovation pipeline. The SRT-007 project, which comprises Gallium [68Ga] PSMA-0057 for diagnostic use and Lutetium [177Lu] PSMA-0057 for therapeutic use, has attracted approximately RMB 32.19 million in R&D investment to date, underscoring Fosun Pharma’s commitment to nuclear medicine and potentially strengthening its competitive position in precision cancer diagnosis and treatment if subsequent trial stages prove successful.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical’s subsidiary, Shanghai Zhaohui Pharmaceutical Company Limited, has received approval from the National Medical Products Administration to begin Phase III clinical trials for a Ketoprofen Patch in China. This drug is intended for analgesic and anti-inflammatory uses, targeting conditions such as lower back pain, osteoarthritis, and rheumatoid arthritis. The approval marks a significant step in the company’s research and development efforts, potentially enhancing its market position and offering new treatment options for patients.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Guilin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration of Foscarnet Sodium Injection. This approval allows the drug to be used for treating cytomegalovirus retinitis in AIDS patients and acyclovir-resistant herpes simplex virus infections in patients with compromised immune systems, potentially strengthening the company’s position in the pharmaceutical market.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Fosun Pharma Industrial, has received approval from the National Medical Products Administration to commence a Phase I clinical trial for FXS0887 Tablets, intended for the treatment of advanced malignant solid tumors. FXS0887 is an innovative small molecule drug that inhibits ATR kinase activity, demonstrating significant anti-tumor efficacy in preclinical studies, which positions the company to potentially enhance its standing in the oncology sector.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has had its drug registration application for Heparin Sodium Injection accepted by the National Medical Products Administration. This drug is intended for multiple medical uses, including the prevention and treatment of various thromboembolic conditions, and its acceptance marks a significant step in the company’s expansion of its pharmaceutical offerings, potentially enhancing its competitive position in the market.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical announced the results of its 2025 second extraordinary general meeting, where the election of an executive director was a key agenda item. The meeting, compliant with relevant legal and corporate governance standards, saw participation from a significant number of shareholders and proxies, with no opposition to the proposed resolutions, indicating strong shareholder support and stable governance.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced the composition of its board of directors, which consists of 12 members, including executive, non-executive, independent non-executive, and employee directors. The announcement also detailed the membership of five specialized committees, highlighting the roles and functions of each board member. This update on the board’s structure could influence the company’s strategic direction and governance, impacting stakeholders’ interests.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical has announced a series of continuing connected transactions, including the CQ Pharma Mutual Supply Framework Agreement, the Framework Tenancy Agreements, and the Fosun International Mutual Supply Framework Agreement. These agreements, set to commence in 2026, involve mutual supply and leasing arrangements with CQ Pharma Holdings and Fosun International, highlighting Fosun Pharma’s strategic partnerships and operational expansions. The transactions are structured to comply with Hong Kong Listing Rules, ensuring they are conducted on normal commercial terms and are in the interests of the company and its shareholders.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical announced that its subsidiary’s drug registration application for Luvometinib Tablets, intended for treating pediatric patients with Langerhans cell histiocytosis, has been accepted by China’s National Medical Products Administration and prioritized for review. This development signifies a strategic advancement for Fosun Pharma in expanding its drug offerings and strengthening its position in the pharmaceutical market, potentially impacting stakeholders positively by addressing unmet medical needs in pediatric care.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Shanghai Zhaohui Pharmaceutical Company Limited, has received acceptance for its drug registration application for Polyethylene Glycol (3350) Electrolytes Powder by the National Medical Products Administration. This drug is intended for treating chronic constipation and represents a significant investment in research and development by the company, totaling approximately RMB6.21 million. The acceptance of this application could enhance Fosun Pharma’s market positioning in the pharmaceutical industry, particularly in China, where the demand for such treatments is growing.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the scheduling of its 2025 second extraordinary general meeting (EGM) to be held on December 2, 2025, in Shanghai. The primary agenda is to elect Mr. Liu Yi as an executive director. This meeting reflects the company’s ongoing efforts to strengthen its leadership structure, which could have implications for its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical has announced the first grant under its 2025 A Share Option Scheme, issuing 4,535,100 A Share Options to 195 participants. This grant, representing approximately 0.1698% of the company’s total shares, includes connected transactions exempt from further shareholder approval due to minimal percentage ratios, reflecting a strategic move to incentivize employees and align their interests with the company’s growth objectives.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical has announced the first grant under its 2025 H Share Restricted Stock Unit (RSU) Scheme, which was approved by shareholders. The grant involves 195 eligible employees, including key executives, receiving a total of 10,589,500 RSUs. This initiative is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical has announced a revision of its annual cap for continuing connected transactions under the Fosun International Mutual Supply Framework Agreement for 2025. The adjustment increases the cap from RMB70 million to RMB90 million to accommodate additional transactions needed for business development in the last quarter of 2025. This revision reflects the company’s strategic efforts to meet growing service demands and aligns with Hong Kong Listing Rules, ensuring compliance without requiring independent shareholders’ approval.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical has announced the proposed spin-off listing of its subsidiary, Fosun Adgenvax, on the Hong Kong Stock Exchange. Fosun Adgenvax specializes in vaccines and has several products approved for marketing in mainland China, with others in various stages of clinical trials. This strategic move aims to enhance Fosun Adgenvax’s market presence and operational focus, though the listing is still in the preliminary planning stage.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has released its unaudited third quarterly report for 2025, covering the period ending on September 30. The report is prepared in accordance with PRC Accounting Standards and assures stakeholders of its accuracy and completeness, as warranted by the company’s board and senior management.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical announced the approval for drug registration of one of its subsidiaries, which marks a significant milestone in its operational capabilities. This approval is expected to enhance the company’s market position and could have positive implications for its stakeholders, reflecting the company’s ongoing commitment to expanding its pharmaceutical offerings.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical announced the results of its 2025 first extraordinary general meeting, where several resolutions were voted on. Key stakeholders, including directors and major shareholders, abstained from voting on resolutions related to the A Share Option Scheme, H Share RSU Scheme, and other agreements due to their material interests, ensuring compliance with governance practices.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical announced that its board of directors will meet on October 28, 2025, to consider and approve the company’s third-quarter results for the nine months ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its stakeholders and market positioning.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical announced the resignation of Mr. Wu Yifang as a non-executive director due to personal work reassignment, effective September 30, 2025. The company proposed the appointment of Mr. Liu Yi as an executive director, subject to shareholder approval. Mr. Liu, currently the CEO and president of the company, has extensive experience in medical devices and diagnostics, and holds several leadership roles within the company and its subsidiaries.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
Shanghai Fosun Pharmaceutical has announced the composition of its board of directors, which includes a mix of executive, non-executive, independent non-executive, and employee directors. The board is supported by five specialized committees, each chaired and populated by different board members, indicating a structured approach to governance and strategic oversight.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.